Datasets:

adi789

/

merged

like 0

GENETIC SUBGROUPS INFORM ON PATHOBIOLOGY IN ADULT AND PEDIATRIC BURKITT LYMPHOMA.

DA-EPOCH-R improves the prognosis of patients with double-expressor lymphoma: A single-center retrospective study and meta-analysis.

Establishment and characterization of a new activated B-cell-like DLBCL cell line, TMD12.

Primary diffuse large B-cell lymphoma of orbit: A population-based analysis.

Charlson Comorbidity Index (CCI) in Diffuse Large B-cell Lymphoma: A New Approach in a Multicenter Study.

Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China.

Correlation study of PD-L1, CD4, CD8, and PD-1 in primary diffuse large B-cell lymphoma of the central nervous system.

The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review.

The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi.

Overexpression of interleukin-20 correlates with favourable prognosis in diffuse large B-cell lymphoma.

Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder.

Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population.

B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.

Lymphomas Affecting the Sublingual Glands: A Clinicopathological Study.

Disease-Defining Molecular Features of Primary Cutaneous B-Cell Lymphomas: Implications for Classification and Treatment.

A survey across orbital lymphoma in Poland: Multicenter retrospective study of polish lymphoma research group (PLRG).

Knockdown of the long non-coding RNA CACNA1G-AS1 enhances cytotoxicity and apoptosis of human diffuse large B cell lymphoma by regulating miR-3160-5p.

Visceral fat area and albumin based nutrition-related prognostic index model could better stratify the prognosis of diffuse large B-cell lymphoma in rituximab era.

Occurrence of MYD88L265P and CD79B mutations in diffuse large b cell lymphoma with bone marrow infiltration: A case report.

Next-Generation Sequencing Highlights of Diffuse Large B-cell Lymphoma in a Tertiary Care Hospital in North India.

LASSO Model Better Predicted the Prognosis of DLBCL than Random Forest Model: A Retrospective Multicenter Analysis of HHLWG.

Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis.

Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study.

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.

Non-Hodgkin's lymphoma masquerading as splenic abscess: A case report.

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.

Lymphomas mimicking neuroinflammatory diseases - A diagnostic conundrum worth revisiting.

New Approval for Drug Treating Large B-Cell Lymphoma.

Expression and Significance of Cyclin-Dependent Protein Kinase 6 in Diffuse Large B-Cell Lymphoma.

Epidemiology and Determinants of Survival for Primary Intestinal Non-Hodgkin Lymphoma: A Population-Based Study.

Study on influencing factors of anthracycline-induced subclinical cardiotoxicity in DLBCL patients administered (R)-CHOP.

Primary diffuse large B-Cell lymphoma of the uterine cervix with severe lower urinary tract Symptoms: A rare case report and review of the literature.

Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications.

Gastric DLBCL clonal evolution as function of patient age.

Integrated Geriatric Assessment and Treatment Effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trial.

Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study.

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma.

Predict DLBCL patients' recurrence within two years with Gaussian mixture model cluster oversampling and multi-kernel learning.

Double/triple hit lymphoma in the gastrointestinal tract: clinicopathological features, PD-L1 expression and screening strategy.

Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.

Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo.

Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.

Effect of infection with hepatitis B virus on the survival outcome of diffuse large B-cell lymphoma in the prophylactic antiviral era.

Secondary Cardiac Involvement From Diffuse Large B-cell Lymphoma: A Case Report.

Prognostic significance of pretreatment red blood cell distribution width in primary diffuse large B-cell lymphoma of the central nervous system for 3P medical approaches in multiple cohorts.

Case report: Recurrent syncope as initial symptom in a patient with neck lymphoma.

Post-chemotherapy pneumonia in Chinese patients with diffuse large B-cell lymphoma: Outcomes and predictive model.

Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma.

Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma.

SMYD3 promotes aerobic glycolysis in diffuse large B-cell lymphoma via H3K4me3-mediated PKM2 transcription.

A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.

Physical activity and the risk of non-Hodgkin lymphoma subtypes: A pooled analysis.

Detection of DLBCL by pixel purity index and iterative linearly constrained minimum variance into hyperspectral imaging analysis.

Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.

An artificial intelligence system applied to recurrent cytogenetic aberrations and genetic progression scores predicts

Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions.

Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression.

Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: results from the phase Ib PORTIA study.

A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma.

Genetic associations with lymphomas in Polish patients: A pooled-DNA genome-wide association analysis.

Integrative analysis of a necroptosis-related gene signature of clinical value and heterogeneity in diffuse large B cell lymphoma.

Corrigendum: TEOA inhibits proliferation and induces DNA damage of diffuse large B-cell lymphoma cells through activation of the ROS-dependent p38 MAPK signaling pathway.

Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review.

Spectrum and trigger identification of hemophagocytic lymphohistiocytosis in adults: A single-center analysis of 555 cases.

Arrhythmia prevalence, predictors, and impact on hospital-associated outcomes among patients with diffuse large B-cell lymphoma.

Multimodal deep learning model on interim [

Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study MabSCale.

Clinicopathologic Features and Genomic Signature of De Novo CD5 + Diffuse Large B-Cell Lymphoma : A Multicenter Collaborative Study.

Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas.

Patient trajectories after diagnosis of diffuse large B-cell lymphoma-a multistate modelling approach to estimate the chance of lasting remission.

A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting.

Diffuse large B-cell lymphoma with cardiac invasion diagnosed using transesophageal ultrasound-guided bronchoscopic aspiration.

Jaundice as a presenting symptom of large B-cell lymphoma.

Influence of Statins on the Survival Outcomes of Patients with Diffuse Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.

Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation.

Immunogenomic-Based Analysis of Hierarchical Clustering of Diffuse Large Cell Lymphoma.

iRGD-modified exosomes-delivered BCL6 siRNA inhibit the progression of diffuse large B-cell lymphoma.

Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report.

Clinicopathological features of adrenal malignancies: Analysis of hospital-based cancer registry data in Japan.

The use of ICU resources in CAR-T cell recipients: a hospital-wide study.

Sonographic features of primary breast lymphoma: An analysis of 10 cases.

Evidence-based review of genomic aberrations in diffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS): Report from the cancer genomics consortium lymphoma working group.

Non-Hodgkin lymphoma of a palate: A case report of a highly destructive lesion.

Renal Lymphoma Diagnosed on Kidney Biopsy Presenting as Acute Kidney Injury.

Splenic Marginal Zone Lymphoma With Histological Transformation to Hodgkin's Lymphoma.

Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments.

Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia.

Case report: Zanubrutinib-induced dermatological toxicities: A single-center experience and review.

Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy.

Preliminary study of hypoxia markers in diffuse large B-cell lymphoma.

Hemophagocytic lymphohistiocytosis as an onset of diffuse large B-cell lymphoma: A case report.

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma.

Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma.

PHOSPHO1 Serves as a Key Metabolism-Related Biomarker in the Tumorigenesis of Diffuse Large B-cell Lymphoma.

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma.

Case Report: Immune Microenvironment and Mutation Features in a Patient With Epstein-Barr Virus Positive Large B-Cell Lymphoma Secondary to Angioimmunoblastic T-Cell Lymphoma.

Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis.

An Oncological Emergency: Severe Type B Lactic Acidosis From Warburg Effect in Diffuse Large B-cell Lymphoma.